Earns small revenues from contract cell therapy development and manufacturing services and from proof-of-concept collaborations applying its 3D cell expansion platform to agriculture and food; it is funded mainly by equity raises, grants and a loan while developing placenta-derived cell therapies, regenerative aesthetic products, and cultivated meat, coffee and cacao technologies.
